A mini-review on clinical studies of Molnupiravir for COVID-19 conducted in selected Asian countries
1 Pharmacy Department, San Pedro College, Davao City, Philippines, 8000.
2 The Graduate School, Centro Escolar University, Manila, Philippines, 1008.
3 Internationalization and Linkages Office, San Pedro College, Davao City, Philippines, 8000.
Review Article
GSC Biological and Pharmaceutical Sciences, 2022, 18(03), 126–129.
Article DOI: 10.30574/gscbps.2022.18.3.0105
Publication history:
Received on 11 February 2022; revised on 13 March 2022; accepted on 15 March 2022
Abstract:
The key goal of this mini review article is to provide enough data and info on the several clinical trials conducted in some number of countries in the Asia on the use of the drug Molnupiravir for Coronavirus disease 2019 (COVID-19). It is caused by severe acute respiratory syndrome coronavirus 2 has extended across the globe in the previous years. Vaccines and antiviral agents were being tested for their efficacies in order to prevent the occurrence of the disease. An antiviral agent, Molnupiravir which is ribonucleoside analog which is a prodrug that can be converted to its active form intracellularly. There were countries like USA and United Kingdom conducted the preliminary clinical trials for the efficacy of this drug. In the Asian region, countries like Japan, Israel, Philippines, Russia, South Korea and Taiwan participated in the clinical studies for Molnupiravir which is under Phase 3 clinical trial. Doses from 200 – 800 mg/kg were utilized in the studies. These certain doses are well tolerated and there were no severe adverse effects that were noted. Thus, Molnupiravir is a potential antiviral agent that can be utilized to treat and prevent COVID-19 infections and endeavored to be fully established.
Keywords:
Molnupiravir; COVID-19; Antiviral; Clinical studies; Asian Region
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
